News
Announcements
The company’s own news page, in the order it published it.
-
9 November 2010
Snowdon awarded a three-year DTRA-TMT contract, up to $8.2 million
Snowdon announced a new three-year contract from the Department of Defense Program, Transformational Medical Technologies (TMT), for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens. Snowdon may receive up to $8.2 million under the Defense Threat Reduction Agency contract. The company is partnering with the Center for Emerging Pathogens at UMDNJ-New Jersey Medical School, under Dr. Nancy Connell, and with the Regional Biocontainment Laboratory under Dr. David Perlin.
-
1 September 2009
NIH award for toxoplasmosis therapies
Snowdon was awarded a grant of $628,000 over two years by the U.S. National Institutes of Health to develop novel therapies for toxoplasmosis, collaborating with Rima McLeod, M.D., at the University of Chicago Medical Center.
-
29 May 2009
FDA contract for computational contaminant detection
Snowdon was awarded a contract with the U.S. Food & Drug Administration to develop computational tools for rapid detection of contaminants in active pharmaceutical ingredients.
-
15 August 2008
NJCST Technology Fellowship
Snowdon was awarded a two-year $150,000 Technology Fellowship grant by the New Jersey Commission on Science & Technology to support Dr. Oyenike Olabisi’s research on novel anti-cancer treatments.
-
11 October 2007
NIH SBIR Phase I award
Snowdon was awarded a $130,000 Phase I Small Business Innovation Research award from the NIH National Institute of Neurological Disorders and Stroke, to support development of technology aimed at the prevention and treatment of protein misfolding diseases such as Alzheimer’s and Parkinson’s disease.
-
23 June 2007
Edison Innovation Award
Snowdon was awarded a two-year $500,000 Edison Innovation Award grant from the New Jersey Commission on Science & Technology to develop lead compounds for the treatment of toxoplasmosis and related parasitic infections.
-
22 March 2007
First investment from FVCG
Snowdon secured $500,000 in venture capital funding from the Foundation Venture Capital Group LLC — the venture firm’s first investment.
2010
The largest award
The three-year DTRA-TMT contract, worth up to $8.2 million, funded discovery and preclinical development of treatments against biowarfare pathogens, in partnership with two UMDNJ centres of excellence.
It complemented the company’s ongoing work on pain, nervous system disorders and other infectious diseases.
Working with Snowdon
Partnering, licensing and scientific enquiries
The company published one inbox for enquiries and one for employment. Both are reproduced as they stood.